Pacific Biosciences of California, Inc. (FRA:P09)
Germany · Delayed Price · Currency is EUR | Market Cap | 585.68M +23.0% |
| Revenue (ttm) | 139.41M +2.0% |
| Net Income | -115.00M |
| EPS | -0.38 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150 |
| Open | 1.790 |
| Previous Close | 1.861 |
| Day's Range | 1.790 - 1.844 |
| 52-Week Range | 0.928 - 2.970 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About FRA:P09
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified... [Read more]
Financial Performance
In 2025, FRA:P09's revenue was $160.01 million, an increase of 3.89% compared to the previous year's $154.01 million. Losses were -$546.38 million, 76.3% more than in 2024.
Financial numbers in USD Financial StatementsNews
PacBio price target raised to $2.50 from $1.50 at Stephens
Stephens analyst Mason Carrico raised the firm’s price target on PacBio (PACB) to $2.50 from $1.50 and keeps an Overweight rating on the shares in conjunction with the firm’s Q3…
PacBio announces multi-year strategic collaboration with Verily Health
PacBio (PACB) and Verily Health announced a multi-year strategic collaboration to integrate PacBio HiFi sequencing with Verily Health’s governed data and AI platform. The collaboration will link PacBi...
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows Verily Pre will connect PacBio HiFi Sequencing with governed cloud a...
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on Wedne...
PacBio, TychoBio collaborate to generate full-length RNA data
PacBio (PACB) and TychoBio announced a collaboration to generate full-length RNA data that TychoBio will use to train models for RNA therapy design. Under the terms of the agreement, TychoBio…
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models PacBio Kinnex sequencing will generate full-length transcript data to help advance T...
Pacific Biosciences of California Slides: Canaccord Bus Tour presentation
Pacific Biosciences of California has posted slides in relation to its latest quarterly earnings report, which was published on September 29, 2026.
Pacific Biosciences of California Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Execution is focused on clinical market expansion, SPRQ-Nx reagent adoption, and high throughput platform development. Multi-use chip technology and software integration are expected to drive gross margin growth, with clinical consumables and new customer segments fueling long-term sustainability.
PacBio assumed with a Neutral at UBS
UBS assumed coverage of PacBio (PACB) with a Neutral rating and $1.35 price target The firm initiated and resumed 25 life science and diagnostics tools companies. UBS views life science…
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference
MENLO PARK, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participat...
Pacific Biosciences of California Transcript: Canaccord Genuity's 46th Annual Growth Conference
Q2 revenue reached $39 million, driven by strong clinical consumables growth and major fleet expansions. The SPRQ-Nx launch and slower Vega demand led to revised guidance, while operational restructuring aims to cut costs and focus on clinical markets. Large-scale genomics deals and new product launches are expected to drive significant revenue and margin improvements by 2027–2028.
PacBio CEO Christian Henry steps down, Mark Van Oene succeeds
PacBio (PACB) announced that its board of directors has appointed Mark Van Oene as president and CEO, effective August 5. Van Oene, who has served as COO, succeeds Christian Henry,…
PacBio cuts FY26 revenue view to $155M-$165M from $165M-$175M
Consensus $167.43M. The company said, “PacBio (PACB) expects revenue for the full year 2026 to be in the range of $155 million to $165 million.”
Pacific Biosciences of California Earnings Call Transcript: Q2 2026
Leadership transitioned to Mark Van Oene as CEO, with a strategic focus on clinical market expansion and operational efficiency. Q2 revenue was $39 million, flat year-over-year, with strong clinical adoption but ongoing funding and cost headwinds. 2026 guidance was lowered, and cash flow breakeven is now expected in 2028.
Pacific Biosciences of California Slides: Q2 2026
Pacific Biosciences of California has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Pacific Biosciences of California Earnings release: Q2 2026
Pacific Biosciences of California released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Pacific Biosciences of California Quarterly report: Q2 2026
Pacific Biosciences of California has published its Q2 2026 quarterly earnings report on August 5, 2026.
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
Christian Henry to Transition from President and Chief Executive Officer Following Six Years of Leadership; Effective August 5, 2026 Christian Henry to Transition from President and Chief Executive Of...
PacBio Announces Second Quarter 2026 Financial Results
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026.
PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system
Vega SPRQ-Nx chemistry to deliver up to 90 Gb per run at 40% lower cost per gigabase, with single-shift runs and new workflow controls for regulated labs Vega SPRQ-Nx chemistry to deliver up to 90 Gb ...
PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
MENLO PARK, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate...
PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2026 financial results on Wedn...
Pacific Biosciences of California Transcript: Status update
HiFi sequencing advances enable high-accuracy, long-read microbial genomics at competitive costs, with new protocols improving throughput and resolution. Research using these methods revealed specific microbial variants linked to rUTI and demonstrated superior performance in metapangenomics, enhancing classification and functional analyses.
Pacific Biosciences of California Transcript: Jefferies Global Healthcare Conference 2026
Record consumable growth and a landmark Basecamp AI deal highlight strong momentum, while SPRQ-Nx chemistry and clinical adoption are set to drive higher utilization and margins in the second half. Academic and government demand remains weak, but hospital and commercial segments are expanding.
Pacific Biosciences of California Transcript: AGM 2026
The meeting addressed four key proposals, all of which were approved, including director elections, auditor ratification, executive compensation, and an equity plan amendment. No questions were submitted by stockholders.